SCHEMBL3292279

SCHEMBL3292279

CCOC(=O)c1cn(-c2ccccc2)c2nc(NCCN3CCCCC3)ncc2c1=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 15/20 0.53
RAB9A P51151 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 3/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NTRK1 P04629 1/20 0.41
KIT P10721 1/20 0.41
SRC P12931 1/20 0.41
FLT3 P36888 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3291092 0.99 CSF1R (0.54) CSF1RRAB9ANPSR1ALDH1A1POLB
SCHEMBL3290631 0.94 CSF1R (0.56) CSF1RRAB9ANPSR1POLBKDM4E
SCHEMBL3293646 0.92 CSF1R (0.59) CSF1RALDH1A1POLBKDM4EMEN1
SCHEMBL3293822 0.89 CSF1R (0.61) CSF1RNTRK1KITSRCFLT3
SCHEMBL3293865 0.87 CSF1R (0.70) CSF1RNTRK1KITSRCFLT3
SCHEMBL3291667 0.87 CSF1R (0.53) CSF1RKITSRCFLT3
SCHEMBL3290585 0.87 CSF1R (0.54) CSF1RALDH1A1POLBKDM4EMEN1
SCHEMBL3291637 0.87 CSF1R (0.65) CSF1RNTRK1KITSRCFLT3
SCHEMBL3292576 0.86 CSF1R (0.66) CSF1RNTRK1KITSRCFLT3
SCHEMBL3291302 0.85 CSF1R (0.49) CSF1RRAB9ANPSR1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728003-B2 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-06-01 US disclosed
EP-1945637-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-23 EP disclosed
WO-2007033137-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR CSF1R 598/4885RAB9A 2982/4885NPSR1 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.